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Abstract
Islet transplantation is an effective treatment for insulin-dependent diabetes, 
but the shortage of donors is a problem. To overcome this, porcine islets have been 
widely studied as an alternative source. This chapter focuses on recent advances in 
porcine islet transplantation, placing particular emphasis on new transgenic pig 
models, islet encapsulation, and biological safety. Genetic modifications aimed 
at reducing the immunogenicity of islet cells to prolong graft survival or improve 
insulin secretory function have been reported. Microencapsulation and macro-
encapsulation of porcine islets may be able to control rejection with little or no 
immunosuppression. Also, the risk of porcine endogenous retrovirus infection is 
considered low because several clinical and preclinical studies have found no such 
evidence. Appropriate pathogen screening, animal selection, and microbiological 
and quality control measures should improve the safety and efficacy of porcine islet 
transplantation in future clinical trials.
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1. Introduction
The islet transplantation protocol used for patients with type 1 diabetes, pub-
lished by a team of researchers at the University of Alberta in 2000, was called the 
Edmonton Protocol and became the starting point for clinical islet transplantation 
[1]. The characteristics of the Edmonton Protocol were that multiple transplants 
were performed using multiple donors to transplant sufficient amounts of islets, 
no steroids were used for immunosuppression, and transplants were performed as 
soon as possible after islet isolation.
Clinical results were reported 5 years after the Edmonton Protocol was 
announced [2], and several problems were identified. For example, the insulin-
free status is not sustained for a long time, the probability of being able to 
obtain islets of sufficient quality and quantity for transplantation even with 
islet isolation is about 50%, and there were many side effects, mainly from 
immunosuppressants.
Islet transplantation has been found to stabilize blood glucose levels and could 
prevent severe hypoglycemia, defined as hypoglycemia requiring another person’s 
assistance. Because severe hypoglycemia can be life-threatening for patients with 
type 1 diabetes, islet transplantation will likely be positioned as a measure for 
preventing severe hypoglycemia. Indeed, allogeneic islet transplantation is an estab-
lished treatment for severe hypoglycemia in Canada and other European countries. 
In addition, in 2016, a phase 3 clinical trial of allogeneic islet transplantation for 
type 1 diabetes patients with a history of severe hypoglycemia found that islet trans-
plantation has a preventive effect for severe hypoglycemia [3]. Therefore, allogeneic 
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islet transplantation has also come to be recognized as standard treatment for 
severe hypoglycemia in the United States. Data on allogeneic islet transplantation 
are registered in the Collaborative Islet Transplant Registry (CITR). According 
to CITR data, the C-peptide positivity rate after islet transplantation alone was 
80% after 1 year and 61% after 3 years, but the severe hypoglycemia prevention 
rate was 94 and 88%, respectively. This indicates that even if the concentration of 
C-peptide is below the lower limit of detection for a positive result (0.3 ng/ml), it 
would be effective in stabilizing blood glucose levels and preventing hypoglycemia. 
According to the data from the International Pancreas Transplant Registry, the 
pancreatic graft survival rate in simultaneous kidney and pancreas transplantation 
was 89% at 1 year and 82% at 3 years after transplantation. In other words, islet 
transplantation outperforms simultaneous pancreas and kidney transplantation 
in terms of rates of preventing severe hypoglycemia. The current status and direc-
tion of beta cell replacement therapy were discussed at a consensus meeting of the 
beta cell replacement therapy opinion leaders held at Oxford University in 2014 
[4]. According to the consensus report, there are 15–20 million patients with type 
1 diabetes worldwide, they are mostly at >20 years after onset of type 1 diabetes, 
1 in 6 patients develop hypoglycemia unawareness, and ~10% of deaths in type 1 
diabetes patients are due to hypoglycemia. It was announced that β cell replace-
ment therapy was optimal for hypoglycemia in patients with hard-to-control type 1 
diabetes. However, only 0.1% of patients with type 1 diabetes could receive beta cell 
replacement therapy due to a shortage of donors. In Japan, cardiac arrest donor islet 
transplantation [5] and living donor islet transplantation [6] have been carried out, 
but in order to fundamentally solve the donor shortage, β cell replacement therapy 
not relying on human organ donors is considered essential. Under these circum-
stances, pig organs are attracting attention as an alternative to organs from human 
donors.
2. Pancreatic islet transplantation using porcine islets
To realize successful porcine islet transplantation, exploratory clinical research 
began several decades ago. Table 1 shows an overview of the history of porcine islet 
transplantation. In the 1990s in Sweden, Groth et al. transplanted islet cells from 
fetal pigs into type 1 diabetic patients on immunosuppressants after kidney trans-
plantation [7]. Porcine C-peptide was positive for several months after transplanta-
tion, which indicated that porcine islets were successfully engrafted in the human 
body. Yet, no clinical effect such as a decrease in the amount of insulin injection 
was observed. In other works, Valdes et al. implanted an angioplasty device with 
newborn pig islets and Sertoli cells subcutaneously into type 1 diabetes patients 
[8]. Eleven patients received additional transplantation 6–9 months after the initial 
transplantation, and four received additional transplantation in the third year. Two 
patients achieved insulin-free status for several months after transplantation. In 
New Zealand, Elliott et al. transplanted newborn pig islets encapsulated in hydrogel 
microcapsules into the peritoneal cavity of type 1 diabetic patients. Because the 
islets were embedded in the immunoisolation capsule, no immunosuppressant was 
used. Insulin and glucagon staining of encapsulated pig islets, which were removed 
after 9.5 years of transplantation, showed that the encapsulated pig islets could be 
engrafted for a long time [9].
Thus, xenogeneic islet transplantation for type 1 diabetes patients using porcine 
islets has been performed in several clinical trials overseas. The risk of infection due 
to xenotransplantation was a concern.
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3. Designated pathogen-free status and porcine endogenous retrovirus
Pigs for clinical use must have a designated pathogen-free (DPF) status, which 
means they are free of pathogens that can infect humans and pigs [10]. DPF status 
is achieved by delivering a piglet by cesarean section from a sow that has been con-
firmed to be free of transplacental pathogens, and after cleaning and decontamina-
tion, the piglet is placed in a biosecure barrier facility.
These facilities are defined at several levels. First, it is necessary that the facility 
itself be sited away from the pig farming facility. The breeding building must be 
completely isolated from the outside environment with an air filter, water decon-
tamination system, radiation sterilization, and autoclave for all incoming materials. 
Piglets are fed with pasteurized milk, not breast milk, and enteric bacteria are pro-
vided separately. For waste disposal, especially liquid waste, special consideration is 
necessary to avoid backflow. Staff must pass through antiseptic showers both when 
entering and exiting the facility and must change into special sterilized clothes. 
Routine health checks of personnel are also conducted. In general, all procedures 
must follow standard operative procedures. It is also important to incorporate cur-
rent good manufacturing practices in accordance with regulatory guidelines.
Nevertheless, in coculture of PK-15 pig kidney cell line (PK15 cells), and human 
fetal kidney cells 293 (HEK293 cells), infection of HEK293 cells by porcine endog-
enous retrovirus (PERV) naturally released from PK15 cells has been reported [11]. 
The problem of PERV infection via porcine xenotransplantation has emerged, 
and because PERV-A and PERV-B are integrated into all porcine genes, they are 
extremely difficult to eliminate. Thus, with regard to PERV, instead of exclusion, 
denial of infectivity and monitoring of transplanted patients and their close rela-
tives are recommended.
Year Events Ref.
1994 Groth et al. reported that fetal pig islet transplantation to diabetic patients [7]
1997 Patience et al. reported that PERV could infect human cells [11]
2005 Valdes-Gonzales et al. reported a 4-year course after transplantation of neonatal pig 
islets and Sertoli cells
[8]
2006 Dufrane et al. showed that encapsulated adult porcine islets survived in the cynomolgus 
monkey body for more than 6 months
[12]
2006 Hering et al. achieved long-term insulin-free status in diabetic monkeys by 
transplantation of wild-type adult porcine islets
[13]
2006 Cardona et al. achieved long-term insulin independence in diabetic monkeys by 
transplantation of neonatal porcine islets
[14]
2007 Elliott et al. reported that about 9.5 years after transplantation, encapsulated porcine 
islets were recovered and insulin staining was positive
[9]
2013 Wang et al. commenced neonatal porcine islet transplantation with Tregs at Central 
South University, China
—
2014 Matsumoto et al. reported porcine islet transplantation under New Zealand regulations [23]
2015 Yang et al. announced that they used CRISPR/Cas9 to inactivate all PERVs [31]
2016 Matsumoto et al. reported clinical efficacy with encapsulated pig islet transplantation [24]
2017 Yamaguchi et al. succeeded in creating a mouse pancreas in a rat using blastocyst 
complementation
[32]
Table 1. 
Chronological overview of clinical and preclinical islet xenotransplantation.
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4. Pig islet transplantation experiment using nonhuman primates
Dufrane et al. demonstrated that mature pig islets embedded in alginate cap-
sules and transplanted into cynomolgus monkeys without immunosuppressants 
survived up to 6 months after transplantation [12]. Hering et al. at the University of 
Minnesota reported that wild-type (unmodified) adult porcine islets transplanted 
into the portal vein of rhesus monkeys with streptozotocin-induced diabetes mel-
litus achieved long-term insulin independence [13]. Also, Cardona et al. from the 
University of Alberta reported that wild-type newborn porcine islets transplanted 
into the portal vein of monkeys with pancreatectomy-induced diabetes resulted in 
long-term insulin-free status [14]. Recently, Park et al. reported more advances with 
modification of immunosuppressants [15]. These reports have brought great hope 
for islet transplantation using porcine islets. However, the importance of prevention 
of infections including PERV has been recognized.
5. Guidelines
While xenotransplantation holds great promise for overcoming donor shortages, 
the global problem of xenogeneic infection must be considered. Therefore, in 2008 
the World Health Organization (WHO) held a conference on xenotransplanta-
tion in Changsha, China, and presented the main points as the First WHO Global 
Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials 
[16]. This statement, referred to as the Changsha Communique, is the basis for 
xenotransplantation worldwide. The content summary is shown in Table 2.
Based on the Changsha Communique, in 2009 the International 
Xenotransplantation Association (IXA) announced a consensus statement of condi-
tions for the initiation of clinical trials of porcine islet products for type 1 diabetes 
[17]. This consensus statement consists of seven chapters and addresses the require-
ments of the Changsha Communique. Because remarkable progress has been made 
in research in this field, the statement should be updated.
Since the consensus statement for the initiation of xenogeneic islet transplan-
tation in IXA was announced in 2009, clinical findings of xenotransplantation 
including clinical xenogeneic islet transplantation in New Zealand have been 
accumulated, and the consensus statement was updated in 2016 [18]. The contents 
of the chapters are:
Chapter 1. Key ethical requirements and progress toward the definition of an 
international regulatory framework: ethical requirements and progress toward 
establishing an international regulatory framework.
Chapter 2. Source pigs: pig requirements for donor sources.
Chapter 3. Pig islet product manufacturing and release testing: manufacturing, 
quality control, and release testing.
Chapter 4. Pre-clinical efficacy and complication data required to justify a clini-
cal trial: appropriate pre-clinical trial.
Chapter 5. Strategies to prevent transmission of porcine endogenous retrovi-
ruses: concept and prevention strategy for PERV.
Chapter 6. Patient selection for pilot clinical trials of islet xenotransplantation: 
appropriate patient selection.
Chapter 7. Informed consent and xenotransplantation clinical trials: ideal 
informed consent procedure.
In particular, because PERV infection and cross-species infection did not occur 
at all, these infections were regarded as a “theoretical risk” and were considered 
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unlikely under the adequate control of suitable donors and recipients. In addition, 
clinical data have been accumulated, infection diagnostic techniques have pro-
gressed, clinical protocols have been improved, the risk of PERV-related infection 
is better understood, DPF facilities and dietary restriction methods have advanced, 
and the role of sample archives has been clarified. As a result of these efforts, cost-
effective generation of donor pigs will be possible, and it is expected that porcine 
islets will be delivered to many patients who truly need this treatment modality.
Some countries have responded to this consensus statement. In Japan, the 
Ministry of Health, Labour and Welfare also revised the “guidelines on public 
health infection problems associated with the implementation of xenotransplanta-
tion” in 2016.
1 Xenotransplantation can be used to treat serious diseases such as diabetes, heart disease, and kidney 
disease. Also, patients who cannot currently receive transplants may be able to receive transplants
2 Medical animals can provide high-quality cells, tissues, and organs. Genetically modified animals may 
further improve outcomes. Medical animals are limited to closed colonies. Breeding should be done at 
a well-controlled pathogen-free facility, with high standards for animal welfare. Medical animals are 
verified by testing for the absence of known pathogens and, moreover, must be kept free of infectious 
diseases by continuous observation
3 Xenotransplantation is a complex procedure with risk of rejection, poor graft function, and known or 
unknown infections. There is a risk of developing serious or new infections, and patients, relatives, or 
other humans and animals may be infected
4 Because of the risk to the community at large, clinical trials of xenotransplantation should be 
conducted under strict regulation. Xenotransplantation should not be performed in the absence of 
national regulations. These regulations should have legal basis and be able to prohibit nonregulatory 
transplants. Furthermore, this regulatory framework should ensure transparency to the general public 
and should include both science and ethics
5 Given the risk to the community, the benefit to the patient should be high. In particular, preclinical 
studies should be conducted using animal experiments with predictable effects to demonstrate the 
safety and efficacy recommended by the international scientific community. Proposed clinical trials 
should be assessed by the relevant regulatory authorities to minimize risk
6 Personnel responsible for clinical trials should explain the inclusion criteria in order to justify the 
clinical trial. Patient selection must be done at the patient’s own discretion based on informed consent. 
Patients and relatives must be effectively educated to ensure compliance and minimize risks to 
themselves and to society
7 Participation in xenotransplantation usually takes a long time. Samples from donor animals, patients 
before and after surgery, and all records should be kept. Patients who have had transplants need 
lifetime follow-up, and close relatives may need similar follow-up. The results of clinical trials should 
be analyzed rigorously. Patients who have undergone xenotransplantation should be registered in 
an appropriate database, which should also be able to track donor animals. At the same time, the 
patient’s privacy has to be protected. All records, data, and samples must be prepared for submission to 
regulatory authorities for a designated period
8 The health-care team must have adequate experience and an understanding of the risks to the patient, 
the health-care team itself, and the community. Because of the risk of transmission to the community, 
a system of vigilance and surveillance should be established to ensure that any infection associated 
with the xenotransplant will be identified and addressed immediately
9 There is a need to establish a system for worldwide information exchange, prevention of unregulated 
xenotransplantation, vigilance and monitoring of xenotransplantation, and response in case of 
suspected infection
10 Considering the benefits of successful xenotransplantation, from the early stages, the treatment 
should be considered widely accepted as the treatment is completed, and the public sector is 
recommended to support
Table 2. 
Summary of the contents of the Changsha communique.
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Recently, in response to the resumption of clinical xenotransplanta-
tion, the Third WHO Global Consultation on Regulatory Requirements for 
Xenotransplantation Clinical Trials was held in 2018, and the contents were 
announced as the 2018 Changsha Communique [19]. The points of the revision are:
1. Prohibition of clinical trials in countries without national regulations and 
subsequent prohibition of medical tourism to such countries
2. Emphasis on reproducible preclinical data
3. Development of quality control measures and standards for genetically modi-
fied pigs
4. Deletion of sample retention period requirements
The Communique emphasizes safety while taking into consideration the actual 
situation of clinical xenotransplantation, social conditions, and technological 
advances.
6. Encapsulation of islets
Although islet transplantation has proved to be successful for patients with type 
1 diabetes, one of the limitations is the requirement for lifelong immunosuppres-
sion. An encapsulation strategy that can prevent rejection of xenogeneic islets can 
potentially overcome this challenge (Figure 1). Such capsules have fine holes that 
allow the passage of oxygen, glucose, and insulin but not immune cells. Blocking 
immune cells allows islet transplantation without the need for immunosuppres-
sants. The capsules have been studied in various materials and sizes. There are three 
main sizes: macro, micro, and nano [20, 21]. The macro-capsule is used to seal islets 
in centimeter-order devices, which are easy to handle and can be removed and 
replaced. However, the problem is that substance permeability is low, and foreign 
body reactions are likely to occur, and the survival rate of internal cells is low. The 
microcapsule is several hundreds of micrometers to millimeters order in size, is 
Figure 1. 
Schematic representation of an encapsulated porcine islet. Pancreatic islets isolated from DPF pig are 
encapsulated with an immunoisolation hydrogel. The capsule has fine holes that allow passage of oxygen, 
glucose, and insulin but not immune cells.
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made mainly of hydrogel, and contains one to several islets. It is compatible in terms 
of substance permeability and immune isolation ability. However, it is too large 
for endovascular transplantation and recovery after transplantation is difficult. 
The nano-capsule has a thin-layered surface coating enclosing pancreatic islets 
comprising a variety of polymers and therapeutic agents. The permeability is high 
but stability is an issue. In addition, a surface modification with immune-privileged 
cells is another concept of encapsulation. Each of these encapsulation techniques 
has advantages and disadvantages, but the technique is very promising.
7. Micro-encapsulated neonatal porcine islet transplantation
In 1980, Lim and Sun applied microcapsules in diabetes treatment, showing 
prolonged islet graft survival using alginate-poly-l-lysine-polyethyleneimine 
microcapsules [22]. Since then, this promising technology has been considerably 
improved.
In 2014, clinical results were reported in which neonatal porcine islets isolated 
from DPF pigs encapsulated with alginate and poly-(l)-ornithine were transplanted 
in 14 patients with type 1 diabetes [23]. The patients were divided into four groups 
according to transplantation dose, and 5000, 10,000, 15,000, and 20,000 IEQ/kg 
of encapsulated islets were transplanted intraperitoneally, respectively, according 
to body weight. No immunosuppressant was used. After transplantation, in the low-
dose groups of 5000 and 10,000 IEQ/kg, the frequency of occurrence of hypoglyce-
mia unawareness was halved compared to that before transplantation.
In 2016, the same group reported results of a clinical trial in which 5000 and 
10,000 IEQ/kg of encapsulated neonatal porcine islets were transplanted twice at 
intervals of 3 months [24]. After transplantation, HbA1c decreased significantly 
in all patients, and the frequency of occurrence of hypoglycemia unawareness was 
significantly reduced in the group that received a transplant of 10,000 IEQ/kg 
twice. Moreover, the group that received a transplant of 10,000 IEQ/kg maintained 
an average HbA1c of ≤7% over 2 years after transplantation and showed a long-term 
effect. Clinical effects have been shown in islet xenotransplantation.
8. Porcine islet transplantation combined with regulatory T cell (Treg)
A clinical trial of transplantation of neonatal porcine islets and autologous Tregs 
in type 1 diabetes patients is underway and is being conducted by Wang et al., 
Central South University, China (ClinicalTrials.gov Identifier NCT03162237). 
The transplanted dose is 10,000 IEQ/kg of islets, 2 × 106/kg of Tregs, and the 
immunosuppressants are tacrolimus, mycophenolate mofetil, and belatacept. The 
primary end point is stable blood glucose level and prevention of ketoacidosis and 
hypoglycemia and a 30% reduction in required insulin. The authors reported that 
the condition of these patients improved substantially (http://en.xy3yy.com/docu-
ment/show_12/184.html). These results are encouraging and add value to this field 
of research.
9. Gene editing and blastocyst complementation
One of the advantages of xenotransplantation is the possibility of genetic modi-
fication in the donor. Advances in gene editing, such as the CRISPR/Cas9 system, 
have facilitated editing of specific genes.
Xenotransplantation - Comprehensive Study
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Recent advances in genetic engineering and gene editing of donor pigs may over-
come the challenge of islet rejection and improve their engraftment and ability to 
secrete insulin. The required set of genetic modifications will depend on the source 
of islets (fetal, neonatal, and adult), mode of delivery (encapsulated, free), and 
the transplantation site. Genetic modification of pigs has been developed mainly 
via deletion of one or more of the major porcine antigens such as GGTA1, CMAH, 
and β4GalNT2, and/or insertion of human complement (such as hCD46, hCD55, 
and hCD59) which suppress the coagulation reaction [25, 26], and/or knockout or 
insertion of other genes. Simultaneous knockout of two or three major pig antigens 
has been achieved, and consequently the binding of human antibodies to these cells 
is significantly reduced. Other genes include the expression of proteins that inhibit 
co-stimulation of T cells such as hCTLA4Ig [27]. The combinations of multiple gene 
editing were promising [28, 29]. Currently, the modifications being carried out in 
pigs span over 24 genes including coagulation regulatory genes, immune cell regula-
tory genes, and anti-inflammatory genes [30]. Simultaneous modification of more 
than five genes has been performed in some pigs [30]. These genetically modified 
pigs will contribute to the improvement of transplantation outcome.
The technology has also been applied to elimination of PERV, and Yang et al. of 
Harvard University reported inactivation of all PERV genomes using the CRISPR/
Cas9 system [31]. They launched a venture company called eGenesis, aiming to 
create a human friendly medical pig with the added advantage of PERV inactiva-
tion. Thus, it is considered that a medical pig suitable for islet transplantation will 
be created by gene editing technology.
Yamaguchi et al. of the University of Tokyo complemented mouse-induced plu-
ripotent stem cells (iPS), cells with blastocysts of pancreatic-deficient rats, and suc-
ceeded in inducing the rats to develop mouse pancreas [32]. The pancreas derived 
from mouse iPS, which was produced by this blastocyst complementation method, 
was the size of the rat pancreas and had a sufficient number of pancreatic islets that 
could be isolated for transplantation to the mouse. These islets were transplanted 
with small amounts of an immunosuppressant drug to diabetic mice syngeneic with 
the iPS cells to normalize blood glucose levels. In addition, this research group also 
succeeded in inducing apancreatic pigs to produce different pig-derived pancre-
ases by blastocyst complementation [33]. In the future, it may be possible to use a 
human iPS cell line to generate a medical pig for a human pancreas by blastocyst 
complementation. If the patient’s own iPS-derived pancreas can be obtained from 
a pig, it is essentially an autologous transplantation, and it thus becomes possible to 
perform islet transplantation without the need for immunosuppressants.
10. Summary
Allogeneic islet transplantation is being established as a standard treatment for 
hypoglycemia unawareness and severe hypoglycemia, but a shortage of human 
donors has become a problem. Islet xenotransplantation using DPF pigs is consid-
ered as a promising fundamental solution to the donor shortage. However, cross-
species infection, especially PERV infection, poses risks to the community, and 
discussions among key opinion leaders have been implemented by the WHO. As a 
result, the IXA Consensus Statement was published in 2016, envisioning a future 
where cost-effective delivery of islet transplants to diabetic patients is facilitated 
by medical pigs. With the risk of infection always kept in mind, cases of clinical 
islet xenotransplantation have been accumulated, and steady progress has been 
made toward a feasible, safe, and effective treatment for diabetic patients. In 
addition, the development of donor pigs optimal for transplantation using the 
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recently publicized CRISPR/Cas9 technology and blastocyst complementation that 
could enable the creation of an individual’s pancreas in pigs could provide for safer 
and more effective islet xenotransplantation. Proper pathogen screening, animal 
selection, microbiological control, and long-term monitoring of recipients will be 
required for clinical application of porcine islet transplantation.
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